ARTV
Artiva Biotherapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
-12/100
Last price
7.26
▲ 0.13 (1.82%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
7.13
Prev close
7.13
Day high
7.38
Day low
6.95
Volume
665.41K
Market cap
$355.43M
P/E (TTM)
—
52W range
2.71 – 14.53
Day trading desk
Gap from prior close
-0.00%
Prior close 7.13
VWAP
7.21
+0.64% from price
Relative volume
1.46×
Normal
Session range
6.19%
6.95 – 7.38
Position in range
72%
Near session high
ATR (14D)
0.48
6.68% of price
Prior day high
7.16
PDH
Prior day low
6.52
PDL
Bid / ask spread
—
Quote not published
Session volume
583.79K
Avg 400.56K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+3.41%
+1.5%
1M
-35.03%
-36.2%
3M
-21.91%
-26.4%
6M
+9.00%
-9.2%
YTD
+69.46%
+55.2%
1Y
+146.44%
+130.0%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ARTV open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+10.32M
Net buying
Buy transactions
20
10.49M shares
Sell transactions
12
166.87K shares
Net transactions
+32
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
7.49M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 15, 26 | ASLAN FRED M.D. Chief Executive Officer |
STOCK | 110.00K | $0 | Direct |
| Sep 10, 26 | ASLAN FRED M.D. Chief Executive Officer |
STOCK | 45.00K | $0 | Direct |
| Sep 9, 26 | BUSH JENNIFER KINSBRUNER Officer |
STOCK | 45.00K | $0 | Direct |
| Sep 9, 26 | HORAN CHRISTOPHER Chief Technology Officer |
STOCK | 40.00K | $0 | Direct |
| Sep 9, 26 | MIRALLES GINES DIEGO President |
STOCK | 45.00K | $0 | Direct |
| Sep 9, 26 | BANERJEE SUBHASHIS M.D. Officer |
STOCK | 30.00K | $0 | Direct |
| Sep 8, 26 | ASLAN FRED M.D. Chief Executive Officer |
SELL | 23.43K | $255.75K | Direct |
| Sep 3, 26 | BUSH JENNIFER KINSBRUNER Chief Operating Officer |
SELL | 8.39K | $93.61K | Direct |
| Sep 3, 26 | HORAN CHRISTOPHER Chief Operating Officer |
SELL | 10.37K | $115.64K | Direct |
| Sep 3, 26 | ASLAN FRED M.D. Chief Executive Officer |
SELL | 61.89K | $690.39K | Direct |
| Sep 3, 26 | BANERJEE SUBHASHIS M.D. Officer |
SELL | 1.10K | $12.27K | Direct |
| Aug 27, 26 | BANERJEE SUBHASHIS M.D. Officer |
SELL | 8.22K | $98.74K | Direct |
| Aug 27, 26 | BANERJEE SUBHASHIS M.D. Officer |
CONVERSION | 5.31K | $10.19K | Direct |
| Aug 18, 26 | BANERJEE SUBHASHIS M.D. Officer |
SELL | 429 | $5.15K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ASLAN FRED M.D. |
Chief Executive Officer | 1.60M | Stock Award(Grant) |
BANERJEE SUBHASHIS M.D. |
Officer | 170.95K | Stock Award(Grant) |
BUSH JENNIFER KINSBRUNER |
Officer | 374.53K | Stock Award(Grant) |
GC CORP |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
HORAN CHRISTOPHER |
Chief Technology Officer | 323.08K | Stock Award(Grant) |
HUSTON THAD ALLEN |
Chief Financial Officer | 220.00K | Stock Award(Grant) |
KRISHNAMOHAN NEHA |
Chief Financial Officer | 110.00K | Stock Award(Grant) |
MIRALLES GINES DIEGO |
President | 122.50K | Stock Award(Grant) |
RA CAPITAL MANAGEMENT, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
RAYMON HEATHER |
Officer | 148.23K | Sale |
Fundamentals
Market cap$355.43M
Enterprise value$15.89M
Revenue (TTM)—
Gross profit—
EBITDA$-93.46M
Net income$-90.82M
EPS (TTM)$-3.23
Free cash flow$-44.43M
Total cash$349.39M
Total debt$9.85M
Book value / share$7.12
Shares outstanding48.89M
Float19.43M
Short % of float8.33%
Dividend yield0.00%
Beta (5Y)2.41
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.79
PEG ratio—
Price / sales—
Price / book1.02
EV / revenue—
EV / EBITDA-0.17
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-36.58%
Return on assets-22.34%
Debt / equity2.83
Current ratio24.16
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $251.00K | $33.49M | $4.93M | -100.0% |
| Operating revenue | $0 | $251.00K | $33.49M | $4.93M | -100.0% |
| Research & development | $69.54M | $50.33M | $50.25M | $43.98M | +38.2% |
| Selling, general & admin | $20.27M | $17.20M | $13.91M | $20.78M | +17.8% |
| Total operating expense | $89.81M | $67.53M | $64.16M | $64.76M | +33.0% |
| Operating income | -$89.81M | -$67.28M | -$30.67M | -$59.83M | -33.5% |
| Net interest income | $5.96M | $5.35M | -$2.54M | -$1.29M | +11.4% |
| Pre-tax income | -$83.86M | -$58.18M | -$32.69M | -$60.92M | -44.1% |
| Tax provision | — | $0 | $72.00K | $53.00K | — |
| Net income | -$83.86M | -$58.18M | -$32.77M | -$60.98M | -44.1% |
| Net income to common | -$83.86M | -$58.18M | -$32.77M | -$60.98M | -44.1% |
| Basic EPS | -3.43 | -5.81 | -1.41 | -6.51 | +41.0% |
| Diluted EPS | -3.43 | -5.81 | -1.41 | -6.51 | +41.0% |
| EBIT | -$89.81M | -$67.28M | -$30.67M | -$59.83M | -33.5% |
| EBITDA | -$87.21M | -$64.85M | -$28.41M | -$58.67M | -34.5% |
| Basic shares | 24.44M | 11.26M | 23.28M | 9.36M | +117.1% |
| Diluted shares | 24.44M | 11.26M | 23.28M | 9.36M | +117.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $26.70M | $40.23M | $53.50M | $102.53M | — | -33.6% |
| Cash & short-term investments | $108.01M | $185.43M | $76.97M | $102.53M | — | -41.8% |
| Accounts receivable | — | $0 | $1.03M | $525.00K | $468.00K | — |
| Total current assets | $112.67M | $188.63M | $79.82M | $104.67M | — | -40.3% |
| Property, plant & equipment | $17.36M | $20.43M | $24.64M | $27.61M | — | -15.0% |
| Total assets | $130.94M | $209.58M | $105.11M | $133.05M | — | -37.5% |
| Total current liabilities | $13.09M | $12.25M | $12.23M | $25.63M | — | +6.8% |
| Total debt | $10.94M | $14.35M | $16.91M | $19.45M | — | -23.8% |
| Total liabilities | $20.97M | $22.94M | $267.13M | $273.75M | — | -8.6% |
| Retained earnings | -$330.55M | -$246.68M | -$181.31M | -$152.59M | — | -34.0% |
| Shareholder equity | $109.97M | $186.64M | -$162.01M | -$140.70M | — | -41.1% |
| Working capital | $99.58M | $176.38M | $67.59M | $79.05M | — | -43.5% |
| Net tangible assets | $109.97M | $186.64M | -$162.01M | -$140.70M | — | -41.1% |
| Shares issued | 24.60M | 24.29M | 23.28M | 23.28M | — | +1.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$83.86M | -$65.37M | -$28.72M | -$58.79M | -28.3% |
| Depreciation & amortisation | $2.60M | $2.43M | $2.27M | $1.16M | +6.8% |
| Stock-based compensation | $6.82M | $6.98M | $7.05M | $6.58M | -2.3% |
| Change in working capital | -$424.00K | -$325.00K | -$28.28M | -$3.87M | -30.5% |
| Operating cash flow | -$76.75M | -$55.03M | -$47.43M | -$50.83M | -39.5% |
| Capital expenditure | -$2.59M | -$642.00K | -$3.26M | -$6.30M | -303.0% |
| Investing cash flow | $63.41M | -$120.46M | -$25.98M | -$6.30M | +152.6% |
| Share buybacks | $0 | -$4.18M | -$12.00K | -$5.00K | +100.0% |
| Financing cash flow | $9.00K | $162.23M | $24.39M | -$1.26M | -100.0% |
| Free cash flow | -$79.34M | -$55.67M | -$50.69M | -$57.13M | -42.5% |
| End cash position | $27.16M | $40.49M | $53.76M | $102.78M | -32.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $21.93M | $19.31M | $16.99M | $17.63M | $17.86M | — | +13.5% |
| Selling, general & admin | $4.96M | $5.12M | $4.94M | $5.26M | $4.95M | — | -3.0% |
| Total operating expense | $26.89M | $24.43M | $21.93M | $22.90M | $22.81M | — | +10.1% |
| Operating income | -$26.89M | -$24.43M | -$21.93M | -$22.90M | -$22.81M | — | -10.1% |
| Net interest income | $1.89M | $912.00K | $1.16M | $1.37M | $1.56M | — | +106.8% |
| Pre-tax income | -$25.00M | -$23.52M | -$20.77M | -$21.53M | -$21.25M | — | -6.3% |
| Net income | -$25.00M | -$23.52M | -$20.77M | -$21.53M | -$21.25M | — | -6.3% |
| Net income to common | -$25.00M | -$23.52M | -$20.77M | -$21.53M | -$21.25M | — | -6.3% |
| Basic EPS | -0.63 | -0.95 | — | -0.88 | -0.87 | -0.83 | +33.7% |
| Diluted EPS | -0.63 | -0.95 | — | -0.88 | -0.87 | -0.83 | +33.7% |
| EBIT | -$26.89M | -$24.43M | -$21.93M | -$22.90M | -$22.81M | — | -10.1% |
| EBITDA | -$26.20M | -$23.76M | -$21.27M | -$22.23M | -$22.17M | — | -10.2% |
| Basic shares | 39.41M | 24.68M | — | 24.48M | 24.38M | 24.34M | +59.7% |
| Diluted shares | 39.41M | 24.68M | — | 24.48M | 24.38M | 24.34M | +59.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $301.45M | $20.95M | $26.70M | $25.51M | $28.47M | +1,338.6% |
| Cash & short-term investments | $349.39M | $86.78M | $108.01M | $122.97M | $142.37M | +302.6% |
| Total current assets | $352.28M | $88.74M | $112.67M | $129.52M | $149.07M | +297.0% |
| Property, plant & equipment | $15.09M | $16.30M | $17.36M | $18.46M | $19.83M | -7.4% |
| Total assets | $368.63M | $105.95M | $130.94M | $148.86M | $169.39M | +247.9% |
| Total current liabilities | $14.58M | $10.88M | $13.09M | $11.12M | $10.77M | +34.0% |
| Total debt | $9.85M | $10.26M | $10.94M | $11.69M | $13.22M | -4.0% |
| Total liabilities | $21.13M | $18.11M | $20.97M | $19.64M | $20.35M | +16.7% |
| Retained earnings | -$379.07M | -$354.06M | -$330.55M | -$309.78M | -$288.25M | -7.1% |
| Shareholder equity | $347.50M | $87.85M | $109.97M | $129.22M | $149.04M | +295.6% |
| Working capital | $337.69M | $77.86M | $99.58M | $118.41M | $138.30M | +333.7% |
| Net tangible assets | $347.50M | $87.85M | $109.97M | $129.22M | $149.04M | +295.6% |
| Shares issued | 48.89M | 24.72M | 24.60M | 24.54M | 24.39M | +97.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$25.00M | -$23.52M | -$20.77M | -$21.53M | -$21.25M | -6.3% |
| Depreciation & amortisation | $692.00K | $666.00K | $666.00K | $662.00K | $641.00K | +3.9% |
| Stock-based compensation | $1.86M | $1.59M | $1.59M | $1.63M | $1.55M | +17.1% |
| Change in working capital | $2.21M | $506.00K | $4.08M | $391.00K | -$3.41M | +336.6% |
| Operating cash flow | -$20.36M | -$20.95M | -$14.73M | -$19.20M | -$22.98M | +2.8% |
| Capital expenditure | -$415.00K | -$242.00K | -$421.00K | -$600.00K | -$1.05M | -71.5% |
| Investing cash flow | $17.59M | $15.32M | $16.04M | $16.28M | $21.12M | +14.8% |
| Financing cash flow | $283.27M | -$112.00K | -$121.00K | -$37.00K | -$72.00K | +253,018.8% |
| Free cash flow | -$20.77M | -$21.19M | -$15.15M | -$19.80M | -$24.04M | +2.0% |
| End cash position | $301.92M | $21.42M | $27.16M | $25.97M | $28.93M | +1,309.8% |
Options analytics
Put / call volume
56.00
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
5.00
-31.2% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
-50.0%
Calls bid over puts
Call volume
1
Contracts, this expiry
Put volume
56
Contracts, this expiry
Heaviest call OI
10.00
0 contracts
Heaviest put OI
5.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.64 | -0.63 | +2.0% |
| Mar 2026 | -0.84 | -0.95 | -12.7% |
| Dec 2025 | -0.80 | -0.84 | -5.0% |
| Sep 2025 | -0.80 | -0.88 | -10.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.53 | 5 | $0 | 0.0% |
| Next quarter | -0.58 | 5 | $0 | 0.0% |
| Current year | -2.51 | 5 | $0 | 0.0% |
| Next year | -2.61 | 5 | $0 | 0.0% |
Analyst targets & ownership
Mean target$35.80
High target$41.00
Low target$23.00
Implied upside393.11%
Analyst count5
ConsensusSTRONG BUY
Strong buy / Buy1 / 5
Hold0
Sell / Strong sell0 / 0
Held by insiders15.31%
Held by institutions84.22%
Institutions holding100
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
7.14
+1.65% from price
SMA 20
8.17
-11.05% from price
SMA 50
10.01
-27.37% from price
SMA 100
9.44
-23.13% from price
SMA 200
7.90
-7.96% from price
EMA 12
7.50
-3.20% from price
EMA 26
8.44
-14.01% from price
EMA 50
9.14
-20.61% from price
RSI (14)
31.7
Neutral
MACD (12,26,9)
-0.94
Hist -0.02
ATR (14)
0.48
6.67% of price
Realised vol 30D
60.6%
Annualised
Bollinger upper
10.72
20, 2σ
Bollinger lower
5.63
20, 2σ
50 / 200 cross
Golden
10.01 vs 7.90
Trend bias
Below 200
-7.96%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.02
More volatile than market
Correlation to SPY
0.14
Largely independent
Realised vol 30D
60.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-49.3%
Peak to trough
Max drawdown 5Y
-90.7%
Peak to trough
ATR 14
0.48
6.67% of price
Beta (reported)
2.41
5Y monthly, from filing
Short interest
Shares short
2.07M
Prior 2.10M
Change vs prior
-1.5%
Shorts covering
% of float
8.33%
Normal
% of shares out
4.22%
Against total outstanding
Days to cover
7.0
Crowded exit
Float
19.43M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Jun 8, 26 | Needham | MAINTAINED | Buy | Buy |
| May 12, 26 | Needham | MAINTAINED | Buy | Buy |
| May 11, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| May 11, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| May 8, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 4, 26 | Needham | MAINTAINED | Buy | Buy |
| Mar 11, 26 | Needham | MAINTAINED | Buy | Buy |
| Nov 12, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 17, 25 | Wedbush | MAINTAINED | Outperform | Outperform |
| Oct 17, 25 | Needham | MAINTAINED | Buy | Buy |
| May 15, 25 | Needham | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Offering Registrations
S-8 · 2026-09-11
Corporate Changes & Voting Matters
8-K · 2026-08-06
Annual Report to Shareholders
ARS · 2026-08-03
Corporate Changes & Voting Matters
8-K · 2026-07-22
Corporate Changes & Voting Matters
8-K · 2026-05-19
Periodic Financial Reports
10-K/A · 2026-04-30
Corporate Changes & Voting Matters
8-K · 2026-03-10
Corporate Changes & Voting Matters
8-K · 2026-02-24
Headlines
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
GlobeNewswire · 5d ago
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)
GlobeNewswire · 6d ago
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
GlobeNewswire · 14d ago
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
GlobeNewswire · 20d ago
Artiva Biotherapeutics Insider Sold Shares Worth $255,746, According to a Recent SEC Filing
MT Newswires · 27d ago
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
GlobeNewswire · 29d ago
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
GlobeNewswire · 35d ago
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
GlobeNewswire · 61d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.